We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ProBioGen AG, a premier, Berlin-based CDMO for developing and manufacturing complex therapeutic glycoproteins today announced that Dr. Lutz Hilbrich, an experienced biotech executive, has been named Chief Executive Officer, effective June 1, 2020.
Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced the departure of the Chief Executive Officer and member of the Board of D